PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses
Background: Several meta-analyses have reported quantitative data about the diagnostic performance, the prognostic value, the impact on management and the safety of positron emission tomography (PET) including related hybrid modalities (PET/CT or PET/MRI) using different radiopharmaceuticals in pati...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/20/5172 |
| _version_ | 1797515076269244416 |
|---|---|
| author | Giorgio Treglia Ramin Sadeghi Francesco Giovinazzo Federica Galiandro Salvatore Annunziata Barbara Muoio Alexander Stephan Kroiss |
| author_facet | Giorgio Treglia Ramin Sadeghi Francesco Giovinazzo Federica Galiandro Salvatore Annunziata Barbara Muoio Alexander Stephan Kroiss |
| author_sort | Giorgio Treglia |
| collection | DOAJ |
| description | Background: Several meta-analyses have reported quantitative data about the diagnostic performance, the prognostic value, the impact on management and the safety of positron emission tomography (PET) including related hybrid modalities (PET/CT or PET/MRI) using different radiopharmaceuticals in patients with neuroendocrine neoplasms. We performed an umbrella review of published meta-analyses to provide an evidence-based summary. Methods: A comprehensive literature search of meta-analyses listed in PubMed/MEDLINE and Cochrane Library databases was carried out (last search date: 30 June 2021). Results: Thirty-four published meta-analyses were selected and summarized. About the diagnostic performance: <sup>68</sup>Ga-SSA PET yields high diagnostic performance in patients with NETs and PGL; <sup>18</sup>F-FDOPA PET yields good diagnostic performance in patients with intestinal NETs, PGL, NB, being the best available PET method in detecting rMTC; <sup>68</sup>Ga-exendin-4 PET has good diagnostic accuracy in detecting insulinomas; <sup>18</sup>F-FDG PET has good diagnostic performance in detecting aggressive neuroendocrine neoplasms. About the prognostic value: <sup>68</sup>Ga-SSA PET has a recognized prognostic value in well-differentiated NETs, whereas <sup>18</sup>F-FDG PET has a recognized prognostic value in aggressive neuroendocrine neoplasms. A significant clinical impact of <sup>68</sup>Ga-SSA PET and related hybrid modalities in patients with NETs was demonstrated. There are no major toxicities or safety issues related to the use of PET radiopharmaceuticals in patients with neuroendocrine neoplasms. Conclusions: Evidence-based data support the use of PET with different radiopharmaceuticals in patients with neuroendocrine neoplasms with specific indications for each radiopharmaceutical. |
| first_indexed | 2024-03-10T06:40:29Z |
| format | Article |
| id | doaj.art-74b2e5a9e1fa4c538e0c8ab33adf0b5c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T06:40:29Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-74b2e5a9e1fa4c538e0c8ab33adf0b5c2023-11-22T17:41:27ZengMDPI AGCancers2072-66942021-10-011320517210.3390/cancers13205172PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-AnalysesGiorgio Treglia0Ramin Sadeghi1Francesco Giovinazzo2Federica Galiandro3Salvatore Annunziata4Barbara Muoio5Alexander Stephan Kroiss6Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, SwitzerlandNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad 9919991766, IranDipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyDipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyUOC Medicina Nucleare, TracerGLab, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyDepartment of Medicine and Oncology, Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, SwitzerlandDepartment of Nuclear Medicine, Medical University Innsbruck, 6020 Innsbruck, AustriaBackground: Several meta-analyses have reported quantitative data about the diagnostic performance, the prognostic value, the impact on management and the safety of positron emission tomography (PET) including related hybrid modalities (PET/CT or PET/MRI) using different radiopharmaceuticals in patients with neuroendocrine neoplasms. We performed an umbrella review of published meta-analyses to provide an evidence-based summary. Methods: A comprehensive literature search of meta-analyses listed in PubMed/MEDLINE and Cochrane Library databases was carried out (last search date: 30 June 2021). Results: Thirty-four published meta-analyses were selected and summarized. About the diagnostic performance: <sup>68</sup>Ga-SSA PET yields high diagnostic performance in patients with NETs and PGL; <sup>18</sup>F-FDOPA PET yields good diagnostic performance in patients with intestinal NETs, PGL, NB, being the best available PET method in detecting rMTC; <sup>68</sup>Ga-exendin-4 PET has good diagnostic accuracy in detecting insulinomas; <sup>18</sup>F-FDG PET has good diagnostic performance in detecting aggressive neuroendocrine neoplasms. About the prognostic value: <sup>68</sup>Ga-SSA PET has a recognized prognostic value in well-differentiated NETs, whereas <sup>18</sup>F-FDG PET has a recognized prognostic value in aggressive neuroendocrine neoplasms. A significant clinical impact of <sup>68</sup>Ga-SSA PET and related hybrid modalities in patients with NETs was demonstrated. There are no major toxicities or safety issues related to the use of PET radiopharmaceuticals in patients with neuroendocrine neoplasms. Conclusions: Evidence-based data support the use of PET with different radiopharmaceuticals in patients with neuroendocrine neoplasms with specific indications for each radiopharmaceutical.https://www.mdpi.com/2072-6694/13/20/5172PETpositron emission tomographyneuroendocrinemeta-analysisumbrella reviewdiagnostic performance |
| spellingShingle | Giorgio Treglia Ramin Sadeghi Francesco Giovinazzo Federica Galiandro Salvatore Annunziata Barbara Muoio Alexander Stephan Kroiss PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses Cancers PET positron emission tomography neuroendocrine meta-analysis umbrella review diagnostic performance |
| title | PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses |
| title_full | PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses |
| title_fullStr | PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses |
| title_full_unstemmed | PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses |
| title_short | PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses |
| title_sort | pet with different radiopharmaceuticals in neuroendocrine neoplasms an umbrella review of published meta analyses |
| topic | PET positron emission tomography neuroendocrine meta-analysis umbrella review diagnostic performance |
| url | https://www.mdpi.com/2072-6694/13/20/5172 |
| work_keys_str_mv | AT giorgiotreglia petwithdifferentradiopharmaceuticalsinneuroendocrineneoplasmsanumbrellareviewofpublishedmetaanalyses AT raminsadeghi petwithdifferentradiopharmaceuticalsinneuroendocrineneoplasmsanumbrellareviewofpublishedmetaanalyses AT francescogiovinazzo petwithdifferentradiopharmaceuticalsinneuroendocrineneoplasmsanumbrellareviewofpublishedmetaanalyses AT federicagaliandro petwithdifferentradiopharmaceuticalsinneuroendocrineneoplasmsanumbrellareviewofpublishedmetaanalyses AT salvatoreannunziata petwithdifferentradiopharmaceuticalsinneuroendocrineneoplasmsanumbrellareviewofpublishedmetaanalyses AT barbaramuoio petwithdifferentradiopharmaceuticalsinneuroendocrineneoplasmsanumbrellareviewofpublishedmetaanalyses AT alexanderstephankroiss petwithdifferentradiopharmaceuticalsinneuroendocrineneoplasmsanumbrellareviewofpublishedmetaanalyses |